Coherus BioSciences Inc logo

Coherus BioSciences Inc

$ 10.07 +0.7 (+7.47%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 782.69M
Enterprise V:
$ 884.56M
Volume:
1.00M
Avg Vol (2M):
1.14M
Volume:
1.00M
Market Cap $:
782.69M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.14M
Enterprise Value $:
884.56M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.64
Equity-to-Asset -0.04
Debt-to-Equity -19.08
Debt-to-EBITDA -2.16
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.35
Distress
Grey
Safe
Beneish M-Score -3.19
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -4.6
3-Year EPS without NRI Growth Rate -5.8
3-Year FCF Growth Rate 40.7
Name Current Vs Industry Vs History
5-Day RSI 64.28
9-Day RSI 54.3
14-Day RSI 50.31
6-1 Month Momentum % -22.9
12-1 Month Momentum % -35.48

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.17
Quick Ratio 2.95
Cash Ratio 1.96
Days Inventory 248.03
Days Sales Outstanding 167.59
Days Payable 155.39

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4

Financials (Next Earnings Date:2022-11-08 Est.)

CHRS's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CHRS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 276.14
EPS (TTM) ($) -2.98
Beta 0.78
Volatility % 62.97
14-Day RSI 50.31
14-Day ATR ($) 0.652813
20-Day SMA ($) 9.836
12-1 Month Momentum % -35.48
52-Week Range ($) 5.6 - 19.32
Shares Outstanding (Mil) 77.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Coherus BioSciences Inc Filings

Document Form Filing Date
No Filing Data

Coherus BioSciences Inc Analysis

Share your research

Headlines

See More
No news.